Cargando…
Adalimumab in Vogt-Koyanagi-Harada Disease Refractory to Conventional Therapy
Background: No study explores the effectiveness of adalimumab in sight-threatening Vogt-Koyanagi-Harada (VKH) patients in China. Objective: To evaluate the short-term effectiveness and safety of adalimumab (ADA) in patients with sight-threatening Vogt-Koyanagi-Harada (VKH) disease refractory to conv...
Autores principales: | Yang, Shizhao, Tao, Tianyu, Huang, Zhaohao, Liu, Xiuxing, Li, He, Xie, Lihui, Wen, Feng, Chi, Wei, Su, Wenru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789678/ https://www.ncbi.nlm.nih.gov/pubmed/35096888 http://dx.doi.org/10.3389/fmed.2021.799427 |
Ejemplares similares
-
Systemic glucocorticoid-free therapy with adalimumab plus immunosuppressants versus conventional therapy in treatment-naïve Vogt-Koyanagi-Harada disease patients
por: Yang, Shizhao, et al.
Publicado: (2022) -
Insights gained from single-cell analysis of immune cells in tofacitinib treatment of Vogt-Koyanagi-Harada disease
por: Liu, Xiuxing, et al.
Publicado: (2022) -
Rituximab in refractory Vogt–Koyanagi–Harada disease
por: Dolz-Marco, Rosa, et al.
Publicado: (2011) -
Clinical Characteristics and Efficacy of Adalimumab and Low-Dose Methotrexate Combination Therapy in Patients With Vogt–Koyanagi–Harada Disease
por: Hiyama, Tomona, et al.
Publicado: (2022) -
Vogt-Koyanagi-Harada Syndrome: A Diagnostic Conundrum
por: Hussain, Anila, et al.
Publicado: (2021)